NEW YORK, Aug. 7 – Illumina met Wall Street expectations on Tuesday as it posted a second-quarter net loss of $5.9 million, or $0.20 per share, compared with $5.3 million, or $0.25, for the same period last year.

Total revenue in the quarter ended June 30 was $470,000, surpassing the $79,000 that the functional genomics company posted for the second quarter 2000, an increase it attributed to a strong performance by its oligo service business.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.